"We have invested $22.1 million for developing chimeric protein"

Dr J Ramachandran, chairman and founder, GangaGen Biotechnologies shares with BioSpectrum the latest developments about their lead product, a recombinant protein, P128 and the other activities of the company

Q: When will the efficacy studies be completed?
We are looking at completing the efficacy studies by November 2013, which we are planning to start from July this year.

Q: What are the other research initiatives of GangaGen?
Our team is pursuing research on the control of Pseudomonas aeruginosa in burns and wounds. The product is also expected to be valuable in treating P. aeruginosa infections in the lungs of patients with cystic fibrosis. We have generated platform technologies that can be used to address any bacterial infections and also novel, propriety methods for vaccine development. We are developing therapies for gram negative pathogens which are increasingly proving to be multidrug resistant and life threatening.

Q: Speaking of developments, are you looking at raising more funds in future?
Although we started our operation in 2000 in Bangalore as GangaGen Biotechnologies Private Ltd (GBPL), to develop novel therapies for treating antibiotic-resistant infection, we received permission from the Ministry of Commerce and Industry, Government of India on December 21, 2001 to convert GBPL into a fully owned subsidiary of GangaGen, which was incorporated as a Delaware Corporation in August 2001 in the interest of investors in the US and Canada. Since then, we were successful in raising $6.1 million in funding. We are already looking on raising additional funds to the tune of $5million, to take care of clinical trials. Hopefully, we might close this before the end of 2013.

Previous 1 2 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email